It's a Small World After All
The increasing number of US proposals to cut profits for drug companies--usually via price cuts--are far more worrisome to the drug industry than even the Clinton health care proposals of 1993-94. Extrapolating from IMS Health sales data, profits from the US market probably represent considerably more than half of the profits in the worldwide drug industry, a significant change from even a few years ago.
You may also be interested in...
Drug price fixing throughout Europe has long frustrated the pharmaceutical industry, but Pfizer's CEO has singled out France as the worst perpetrator.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.